NZ703095A - Oligonucleotide chelate complex-polypeptide compositions and methods - Google Patents

Oligonucleotide chelate complex-polypeptide compositions and methods

Info

Publication number
NZ703095A
NZ703095A NZ703095A NZ70309513A NZ703095A NZ 703095 A NZ703095 A NZ 703095A NZ 703095 A NZ703095 A NZ 703095A NZ 70309513 A NZ70309513 A NZ 70309513A NZ 703095 A NZ703095 A NZ 703095A
Authority
NZ
New Zealand
Prior art keywords
methods
chelate complex
polypeptide compositions
oligonucleotide chelate
polypeptide
Prior art date
Application number
NZ703095A
Other languages
English (en)
Inventor
Andrew Vaillant
Michel Bazinet
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49581470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ703095(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of NZ703095A publication Critical patent/NZ703095A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2292Thymosin; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/217IFN-gamma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
NZ703095A 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods NZ703095A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648711P 2012-05-18 2012-05-18
US201261695035P 2012-08-30 2012-08-30
PCT/CA2013/050379 WO2013170386A1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods

Publications (1)

Publication Number Publication Date
NZ703095A true NZ703095A (en) 2016-07-29

Family

ID=49581470

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ703095A NZ703095A (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods

Country Status (34)

Country Link
US (1) US9492506B2 (cg-RX-API-DMAC7.html)
EP (1) EP2849798B1 (cg-RX-API-DMAC7.html)
JP (1) JP2015517504A (cg-RX-API-DMAC7.html)
KR (1) KR102068109B1 (cg-RX-API-DMAC7.html)
CN (1) CN104349793B (cg-RX-API-DMAC7.html)
AU (1) AU2013262416B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014028654A2 (cg-RX-API-DMAC7.html)
CA (1) CA2873529C (cg-RX-API-DMAC7.html)
CL (1) CL2014003134A1 (cg-RX-API-DMAC7.html)
CO (1) CO7131387A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140527A (cg-RX-API-DMAC7.html)
CY (1) CY1124345T1 (cg-RX-API-DMAC7.html)
DK (1) DK2849798T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2014000264A (cg-RX-API-DMAC7.html)
EA (1) EA035967B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP14027694A (cg-RX-API-DMAC7.html)
ES (1) ES2873844T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210840T1 (cg-RX-API-DMAC7.html)
HU (1) HUE054875T2 (cg-RX-API-DMAC7.html)
IL (1) IL235548B (cg-RX-API-DMAC7.html)
LT (1) LT2849798T (cg-RX-API-DMAC7.html)
MX (1) MX346239B (cg-RX-API-DMAC7.html)
MY (1) MY168778A (cg-RX-API-DMAC7.html)
NZ (1) NZ703095A (cg-RX-API-DMAC7.html)
PH (1) PH12014502551B1 (cg-RX-API-DMAC7.html)
PL (1) PL2849798T3 (cg-RX-API-DMAC7.html)
PT (1) PT2849798T (cg-RX-API-DMAC7.html)
RS (1) RS62030B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201407599SA (cg-RX-API-DMAC7.html)
SI (1) SI2849798T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100319T1 (cg-RX-API-DMAC7.html)
TW (1) TWI635864B (cg-RX-API-DMAC7.html)
WO (1) WO2013170386A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201408674B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2158316T3 (pl) 2007-05-11 2015-10-30 Adynxx Inc Ekspresja genowa oraz ból
AU2013259402B2 (en) 2012-05-10 2017-12-21 Adynxx, Inc. Formulations for the delivery of active ingredients
TWI620568B (zh) 2012-08-30 2018-04-11 雷普利可公司 用於治療b型肝炎及d型肝炎感染之方法
MX381042B (es) 2014-07-10 2025-03-12 Replicor Inc Uso de un complejo quelato y un anàlogo de neucleòsido o neucleòtido para tratar infecciones de virus de la hepatitis b y hepatitis d.
EP3180434B1 (en) 2014-08-15 2019-07-17 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
SG11202104636XA (en) * 2018-11-08 2021-06-29 Aligos Therapeutics Inc S-antigen transport inhibiting oligonucleotide polymers and methods
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2024255846A1 (en) * 2023-06-16 2024-12-19 Ractigen Therapeutics Oligonucleotide formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769114B2 (ja) * 1993-10-29 1998-06-25 サイクローン・ファーマシューティカルズ ミニマルb型肝炎感染症治療用医薬組成物
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
BR0314236A (pt) * 2002-09-13 2005-08-09 Replicor Inc Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
JP2006519235A (ja) 2003-02-26 2006-08-24 インターミューン インコーポレイティッド ポリエチレングリコール修飾インターフェロン組成物およびその使用方法
KR20060120162A (ko) * 2003-10-27 2006-11-24 버텍스 파마슈티칼스 인코포레이티드 Hcv 치료용 배합물
EP1802643A1 (en) 2004-10-19 2007-07-04 Replicor Inc. Antiviral oligonucleotides
WO2007022642A2 (en) * 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
EP1928498A4 (en) * 2005-09-29 2009-11-11 Cell Biosciences Inc S METHOD FOR THE TREATMENT OF T-CELL DISORDERS WITH TISF
WO2007036016A1 (en) * 2005-09-29 2007-04-05 Replicor Inc. Therapeutic molecules and their uses
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
AU2008334948B2 (en) 2007-12-13 2014-11-20 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
US8361980B2 (en) * 2008-03-07 2013-01-29 Santaris Pharma A/S Pharmaceutical compositions for treatment of microRNA related diseases
CA2764683A1 (en) * 2009-05-28 2010-12-02 Joseph Collard Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
CN102762215A (zh) * 2009-10-16 2012-10-31 葛兰素集团有限公司 Hbv反义抑制剂
SG187165A1 (en) * 2010-08-20 2013-02-28 Replicor Inc Oligonucleotide chelate complexes
TWI620568B (zh) 2012-08-30 2018-04-11 雷普利可公司 用於治療b型肝炎及d型肝炎感染之方法

Also Published As

Publication number Publication date
CA2873529A1 (en) 2013-11-21
SMT202100319T1 (it) 2021-09-14
EP2849798A4 (en) 2016-03-09
CY1124345T1 (el) 2022-07-22
AU2013262416A1 (en) 2014-12-18
MY168778A (en) 2018-12-04
LT2849798T (lt) 2021-08-10
CN104349793B (zh) 2017-11-10
HUE054875T2 (hu) 2021-10-28
MX346239B (es) 2017-03-13
KR20150013309A (ko) 2015-02-04
EA035967B1 (ru) 2020-09-07
HK1204279A1 (en) 2015-11-13
SI2849798T1 (sl) 2021-08-31
BR112014028654A2 (pt) 2017-10-10
IL235548A0 (en) 2015-01-29
US20130309201A1 (en) 2013-11-21
CR20140527A (es) 2014-12-15
TWI635864B (zh) 2018-09-21
TW201408308A (zh) 2014-03-01
CO7131387A2 (es) 2014-12-01
EP2849798B1 (en) 2021-04-07
RS62030B1 (sr) 2021-07-30
PL2849798T3 (pl) 2021-10-18
AU2013262416B2 (en) 2017-05-11
WO2013170386A1 (en) 2013-11-21
DK2849798T3 (da) 2021-05-31
EA201401278A1 (ru) 2015-04-30
KR102068109B1 (ko) 2020-01-21
CN104349793A (zh) 2015-02-11
US9492506B2 (en) 2016-11-15
EP2849798A1 (en) 2015-03-25
CA2873529C (en) 2020-08-18
PH12014502551B1 (en) 2019-10-11
IL235548B (en) 2019-07-31
HRP20210840T1 (hr) 2021-08-06
PH12014502551A1 (en) 2015-01-21
DOP2014000264A (es) 2015-01-31
CL2014003134A1 (es) 2015-02-13
JP2015517504A (ja) 2015-06-22
MX2014014021A (es) 2015-02-10
ES2873844T3 (es) 2021-11-04
ZA201408674B (en) 2016-01-27
SG11201407599SA (en) 2014-12-30
PT2849798T (pt) 2021-05-18
ECSP14027694A (es) 2015-12-31

Similar Documents

Publication Publication Date Title
PH12014502551A1 (en) Oligonucleotide chelate complex-polypeptide compositions and methods
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
IN2015DN01156A (cg-RX-API-DMAC7.html)
TN2015000278A1 (en) Autotaxin inhibitors
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
MY172292A (en) Vectors and sequences for the treatment of diseases
MX349004B (es) Nuevos compuestos.
PH12015500724B1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
MX2015011193A (es) Compuestos antivirales.
IN2014CN00572A (cg-RX-API-DMAC7.html)
MX2015011198A (es) Compuestos antivirales.
MY188071A (en) Pyridone derivatives for the treatment of viral infections and further diseases
MX2015010892A (es) Compuestos antivirales.
MX2015011125A (es) Compuestos antivirales.
IN2014DN10683A (cg-RX-API-DMAC7.html)
MX2015011126A (es) Compuestos antivirales.
CU20140133A7 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
GB201114923D0 (en) Immunogenic proteins and compositions
ZA201407866B (en) Composition for the prevention and treatment of viral infections caused by retroviruses

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 MAY 2018 BY DENNEMEYER + CO

Effective date: 20170428

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 MAY 2019 BY DENNEMEYER + CO.

Effective date: 20181113

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 MAY 2020 BY DENNEMEYER + CO.

Effective date: 20190419

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 MAY 2021 BY DENNEMEYER + CO

Effective date: 20200505

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 MAY 2022 BY CPA GLOBAL

Effective date: 20210401

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 MAY 2023 BY CPA GLOBAL

Effective date: 20220407

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 MAY 2024 BY CPA GLOBAL

Effective date: 20230420

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 MAY 2025 BY CPA GLOBAL

Effective date: 20241116

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 MAY 2026 BY CPA

Effective date: 20251029